{"id":871195,"date":"2025-08-05T18:08:22","date_gmt":"2025-08-05T22:08:22","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date\/"},"modified":"2025-08-05T18:08:22","modified_gmt":"2025-08-05T22:08:22","slug":"cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cumberland-pharmaceuticals-reports-23-revenue-growth-year-to-date\/","title":{"rendered":"Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NASHVILLE, Tenn.<\/span>
\n <\/span>, Aug. 5, 2025<\/span><\/span> \/PRNewswire\/ — Cumberland Pharmaceuticals Inc. <\/b>(Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined net revenues of $10.8 million<\/span> during the second quarter of 2025, a 10% increase over the prior year period. Year-to-date revenues for the first six months of the year totaled $22.6 million<\/span>, representing an increase of 23% over the first half of 2024.<\/p>\n

\n

\n
\n \"Cumberland
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Cumberland<\/span> ended the quarter with approximately $68 million<\/span> in total assets, $40 million<\/span> in liabilities and $28 million<\/span> of shareholders’ equity.<\/p>\n

“We have had a strong first half of the year, especially following the progress of our clinical development programs,” said Cumberland Pharmaceuticals CEO A.J. Kazimi<\/span>. “We look forward to building on this success throughout the remainder of the year as we continue our mission of working together to provide unique products that improve the quality of patient care.”<\/p>\n

\n
\n RECENT COMPANY DEVELOPMENTS INCLUDE:<\/u>
\n <\/b>\n <\/p>\n

\n Vibativ\u00ae<\/sup> 4-Vial Starter Pak Now Available for Vizient Providers<\/b>\n <\/p>\n

\n Cumberland<\/span> recently announced the availability of the Vibativ\u00a0(telavancin) 4-Vial Starter Pak through a new supply arrangement with Vizient Inc., making it accessible to their health care providers nationwide.<\/p>\n

As the country’s largest provider-driven health care performance improvement company, Vizient serves more than 65% of the nation’s acute care providers, including 97% of academic medical centers and 35% of the non-acute market. Through this agreement, Vizient members now have access to Vibativ’s new 4-vial configuration, which supports flexible treatment initiation in both inpatient and outpatient settings for this potentially life-saving therapy.<\/p>\n

\n Pharmacokinetic Analysis Reinforces Vibativ\u00a0Dosing Strategies<\/b>\n <\/p>\n

A comprehensive new pharmacokinetic analysis of Vibativ was published in Antimicrobial Agents and Chemotherapy<\/i> in June 2025<\/span>. The analysis utilizes data from over 1,200 patients across varied demographics and comorbidity profiles. The findings support optimized dosing strategies for patients with different infection severities and renal function levels, reinforcing Vibativ’s critical role in treating life-threatening gram-positive infections.<\/p>\n

\n Ifetroban Clinical Studies<\/b>\n <\/p>\n

In June 2025<\/span>, breakthrough findings from Cumberland’s<\/span> Phase II FIGHT DMD trial, evaluating its ifetroban product candidate in patients with Duchenne muscular dystrophy (“DMD”), were presented at the Parent Project Muscular Dystrophy Annual Conference<\/i>. The findings demonstrated that high-dose ifetroban delivered a 5.4% improvement in cardiac function in patients with DMD. The presentation also included additional biomarker data indicating reduced cardiac damage, which correlated with the clinical findings. These results position ifetroban as a potential treatment for DMD cardiomyopathy \u2013 the leading cause of death in these patients and a critical unmet medical need affecting 90% of DMD patients.<\/p>\n

The top-line FIGHT DMD study findings were also selected for a late-breaking presentation at the Muscular Dystrophy Association’s Clinical & Scientific Conference<\/i> in March 2025<\/span>. In June 2025<\/span>, Cumberland<\/span> completed the comprehensive analysis of the study results, completed its clinical study report and submitted it to the FDA along with a request for an end-of-Phase II meeting.<\/p>\n

Meanwhile, Cumberland<\/span> has been evaluating its ifetroban product candidate in a Phase II clinical program in patients with Systemic Sclerosis. Enrollment in the study was completed this year, and Cumberland<\/span> is monitoring the clinical sites in preparation to lock the database and begin evaluating the results.<\/p>\n

In addition, Cumberland<\/span> has a Phase II clinical study, the FIGHTING FIBROSIS\u2122 trial, underway in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. Patient enrollment is now well underway in medical centers across the U.S. The study design includes both an interim safety analysis, as well as an interim efficacy analysis.<\/p>\n

\n New Study Features Caldolor\u00ae<\/sup> (ibuprofen injection) for Older Patients<\/b>\n <\/p>\n

In May 2025<\/span>, Cumberland<\/span> announced the publication of its study investigating Caldolor (intravenous ibuprofen) in Clinical Therapeutics<\/i>, demonstrating the product’s safety and efficacy for managing post-operative pain in patients 60 years of age and older. The analysis, encompassing over 1,000 older patients from comprehensive post-surgical studies, represents the first such evaluation in this vulnerable population, where traditional pain management options such as opioids carry increased risk.<\/p>\n

\n
\n FINANCIAL RESULTS:<\/u>
\n <\/b>\n <\/p>\n

\n Net Revenue: <\/b>For the second quarter of 2025, net revenues were $10.8 million<\/span> and included $2.8 million<\/span> for Kristalose\u00ae<\/sup>, $3.1 million<\/span> for Sancuso\u00ae<\/sup>, $2.7 million<\/span> for Vibativ\u00ae <\/sup>and $1.6 million<\/span> for Caldolor\u00ae<\/sup>.<\/p>\n

Year-to-date 2025\u00a0net revenues were $22.6 million<\/span>. Year-to-date net revenues by product were $6.2<\/span> million\u00a0for Kristalose, $5.4 million<\/span> for Sancuso, $4.1<\/span> million\u00a0for Vibativ and $2.9<\/span> million\u00a0for Caldolor.<\/p>\n

\n Operating Expenses:<\/b> Total operating expenses were $11.6 million<\/span> for the second quarter of 2025 and $22 million<\/span> for the first half of the year.<\/p>\n

\n Net Income (loss):<\/b> Year-to-date net income was approximately $516,000<\/span> and the second quarter net loss was approximately $741,000<\/span>.<\/p>\n

\n Adjusted Earnings: <\/b>Adjusted earnings for the six months ended 2025 were $2.8 million<\/span>, or $0.18<\/span> per diluted share.<\/p>\n

\n Balance Sheet:<\/b> At June 30, 2025<\/span>, Cumberland<\/span> had approximately $68 million<\/span> in total assets, including $16 million<\/span> in cash and cash equivalents. Liabilities totaled $40 million<\/span>, including $5 million<\/span> on the company’s credit facility. Total shareholders’ equity was $28 million<\/span> on June 30, 2025<\/span>.<\/p>\n

\n
\n EARNINGS REPORT CALL:<\/u>
\n <\/b>\n <\/p>\n

A conference call will be held today, August\u00a05, 2025, at 4:30 p.m. Eastern Time<\/span> to provide a company update and discuss the financial results.<\/p>\n

The link to register is https:\/\/register-conf.media-server.com\/register\/BI0e0cfee6a381408fa7d3d939d82dfa04<\/a>.<\/p>\n

Registered participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a “Call Me” option to have the system automatically call them at the start of the conference.<\/p>\n

A replay of the call will be available for one year and can be accessed via Cumberland’s<\/span> website or by visiting:https:\/\/edge.media-server.com\/mmc\/p\/zpxz72fn<\/a>.<\/p>\n

\n ABOUT CUMBERLAND<\/span> PHARMACEUTICALS:<\/b>\n <\/p>\n

\n Cumberland Pharmaceuticals Inc.<\/b> is the largest biopharmaceutical company founded and headquartered in Tennessee<\/span> and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company’s portfolio of FDA-approved brands includes:<\/p>\n